With reduced leverage and a more disciplined capital allocation framework in place, Cabka enters 2026 in a stronger and more stable position. We expect improvement in revenues and further EBITDA ...
With me on today's call are Rick Wilmer, our Chief Executive Officer, and Mansi Khetani, our Chief Financial Officer. For a ...
22h
Cellectar Biosciences Reports Financial Results for Year Ended 2025 and Provides Corporate Updates
On track to submit Conditional Marketing Authorization for iopofosine I 131 to European Medicines Agency in Q3 2026 for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results